Am­gen at­tor­neys win a megablock­buster patent case, deal­ing No­var­tis a se­vere set­back on biosim­i­lars play

Don’t bet against Am­gen at­tor­neys.

That’s what Umer Raf­fat’s old men­tor Mark Schoen­baum told the Ever­core ISI an­a­lyst when he was prep­ping for a re­cent deep dive on Am­gen’s En­brel.

Like oth­er clas­sic re­marks about Am­gen’s liti­gious na­ture, it was dead on.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.